2017
Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction
Kernan WN, Viscoli CM, Dearborn JL, Kent DM, Conwit R, Fayad P, Furie KL, Gorman M, Guarino PD, Inzucchi SE, Stuart A, Young LH. Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction. JAMA Neurology 2017, 74: 1319-1327. PMID: 28975241, PMCID: PMC5710663, DOI: 10.1001/jamaneurol.2017.2136.Peer-Reviewed Original ResearchConceptsTransient ischemic attackIschemic attackMyocardial infarctionIschemic strokeHigh riskPioglitazone groupInsulin resistanceLower riskCox proportional hazards regression modelProportional hazards regression modelsMedian riskEfficacy of pioglitazoneInsulin Resistance InterventionQualifying ischemic strokePlacebo-controlled trialHazards regression modelsLow baseline riskType 2 diabetesGreater absolute benefitDay of entryFuture strokeHydrochloride therapyPlacebo groupHazard ratioSecondary prevention
2001
A Clinical Trial of Estrogen-Replacement Therapy after Ischemic Stroke
Viscoli C, Brass L, Kernan W, Sarrel P, Suissa S, Horwitz R. A Clinical Trial of Estrogen-Replacement Therapy after Ischemic Stroke. New England Journal Of Medicine 2001, 345: 1243-1249. PMID: 11680444, DOI: 10.1056/nejmoa010534.Peer-Reviewed Original ResearchConceptsEstrogen replacement therapyEstrogen therapyNonfatal strokePostmenopausal womenIschemic strokeCerebrovascular diseasePlacebo-controlled trialTransient ischemic attackOccurrence of strokeRisk of deathIschemic attackFatal strokeMean followPlacebo groupSecondary preventionEstradiol groupFunctional deficitsClinical trialsObservational studyHigh riskWoman's riskTherapyStrokeWomenDeath